JP4847441B2 - Ｈｉｖ感染の治療方法 - Google Patents

Ｈｉｖ感染の治療方法 Download PDF

Info

Publication number
JP4847441B2
JP4847441B2 JP2007504971A JP2007504971A JP4847441B2 JP 4847441 B2 JP4847441 B2 JP 4847441B2 JP 2007504971 A JP2007504971 A JP 2007504971A JP 2007504971 A JP2007504971 A JP 2007504971A JP 4847441 B2 JP4847441 B2 JP 4847441B2
Authority
JP
Japan
Prior art keywords
hiv
compound
inhibitor
hiv infection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007504971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530540A (ja
JP2007530540A5 (cg-RX-API-DMAC7.html
Inventor
ピン−ファン・リン
ベアータ・ノウィッカ−サンズ
グレゴリー・ヤマナカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4847441(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2007530540A publication Critical patent/JP2007530540A/ja
Publication of JP2007530540A5 publication Critical patent/JP2007530540A5/ja
Application granted granted Critical
Publication of JP4847441B2 publication Critical patent/JP4847441B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007504971A 2004-03-24 2005-03-01 Ｈｉｖ感染の治療方法 Expired - Lifetime JP4847441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
US60/555,767 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (3)

Publication Number Publication Date
JP2007530540A JP2007530540A (ja) 2007-11-01
JP2007530540A5 JP2007530540A5 (cg-RX-API-DMAC7.html) 2008-04-17
JP4847441B2 true JP4847441B2 (ja) 2011-12-28

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007504971A Expired - Lifetime JP4847441B2 (ja) 2004-03-24 2005-03-01 Ｈｉｖ感染の治療方法

Country Status (30)

Country Link
US (1) US7776863B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732604B1 (cg-RX-API-DMAC7.html)
JP (1) JP4847441B2 (cg-RX-API-DMAC7.html)
KR (1) KR101158140B1 (cg-RX-API-DMAC7.html)
CN (1) CN1956720B (cg-RX-API-DMAC7.html)
AR (1) AR048333A1 (cg-RX-API-DMAC7.html)
AT (1) ATE474602T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005235116B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509140A (cg-RX-API-DMAC7.html)
CA (1) CA2561146C (cg-RX-API-DMAC7.html)
CY (1) CY1111613T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022420D1 (cg-RX-API-DMAC7.html)
DK (1) DK1732604T3 (cg-RX-API-DMAC7.html)
ES (1) ES2347801T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20104925B (cg-RX-API-DMAC7.html)
HR (1) HRP20100434T1 (cg-RX-API-DMAC7.html)
IL (1) IL178141A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN06436A (cg-RX-API-DMAC7.html)
MY (1) MY144318A (cg-RX-API-DMAC7.html)
NO (1) NO337116B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549778A (cg-RX-API-DMAC7.html)
PE (1) PE20060148A1 (cg-RX-API-DMAC7.html)
PL (1) PL1732604T3 (cg-RX-API-DMAC7.html)
PT (1) PT1732604E (cg-RX-API-DMAC7.html)
RU (1) RU2367439C2 (cg-RX-API-DMAC7.html)
SI (1) SI1732604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI347184B (cg-RX-API-DMAC7.html)
UA (1) UA88463C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005102392A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607959B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8318931B2 (en) 2005-10-28 2012-11-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
ES2462403T3 (es) 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
US8242124B2 (en) * 2008-06-25 2012-08-14 Bristol-Myers Squibb Company Diketopiperidine derivatives as HIV attachment inhibitors
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
RS54055B1 (sr) 2011-01-31 2015-10-30 Bristol-Myers Squibb Company POSTUPCI ZA PRIPREMU JEDINJENJA PROLEKA INHIBITORA VEZIVANJA HIV-a I INTERMEDIJERA
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
EP3313412A4 (en) 2015-06-23 2019-01-16 CytoDyn Inc. INHIBITION OF CCL5 LIGAND BINDING AT CCR5 RECEPTOR AND CHANGING CCR5 / CCL5 AXIS SIGNALING IN INFUSION, CANCER, AUTOIMMUNE AND OTHER DISORDERS
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014380A1 (en) * 2002-08-07 2004-02-19 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348839T1 (de) * 1998-03-02 2007-01-15 Univ North Carolina Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
WO2003049690A2 (en) * 2001-12-12 2003-06-19 Bristol-Myers Squibb Company Hiv integrase inhibitors
CN102153540A (zh) * 2001-12-21 2011-08-17 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014380A1 (en) * 2002-08-07 2004-02-19 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Also Published As

Publication number Publication date
JP2007530540A (ja) 2007-11-01
EP1732604A2 (en) 2006-12-20
GEP20104925B (en) 2010-03-25
US20050215545A1 (en) 2005-09-29
NZ549778A (en) 2010-09-30
DE602005022420D1 (de) 2010-09-02
DK1732604T3 (da) 2010-11-15
UA88463C2 (ru) 2009-10-26
WO2005102392A3 (en) 2006-07-20
CN1956720B (zh) 2010-12-15
HK1096540A1 (en) 2007-06-01
AU2005235116A1 (en) 2005-11-03
US7776863B2 (en) 2010-08-17
RU2006137555A (ru) 2008-04-27
IL178141A0 (en) 2006-12-31
ES2347801T3 (es) 2010-11-04
NO20064547L (no) 2006-10-06
IL178141A (en) 2010-11-30
PL1732604T3 (pl) 2010-12-31
CY1111613T1 (el) 2015-10-07
MY144318A (en) 2011-08-29
HRP20100434T1 (hr) 2010-09-30
AU2005235116B2 (en) 2011-03-31
CN1956720A (zh) 2007-05-02
RU2367439C2 (ru) 2009-09-20
PT1732604E (pt) 2010-09-24
EP1732604B1 (en) 2010-07-21
BRPI0509140A (pt) 2007-09-04
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
CA2561146C (en) 2013-12-24
NO337116B1 (no) 2016-01-25
AR048333A1 (es) 2006-04-19
TW200538117A (en) 2005-12-01
KR20070011322A (ko) 2007-01-24
CA2561146A1 (en) 2005-11-03
ZA200607959B (en) 2008-06-25
WO2005102392A2 (en) 2005-11-03
KR101158140B1 (ko) 2012-06-19
ATE474602T1 (de) 2010-08-15
IN2012DN06436A (cg-RX-API-DMAC7.html) 2015-10-09
TWI347184B (en) 2011-08-21

Similar Documents

Publication Publication Date Title
JP4847441B2 (ja) Ｈｉｖ感染の治療方法
WO2005102391A1 (en) Combinations for the treatment of aids or hiv infections
Flexner Antiretroviral agents and treatment of HIV infection
US10426780B2 (en) Antiviral therapy
De Clercq Emerging anti-HIV drugs
Romanelli et al. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity
WO2005102328A1 (en) Methods of treating hiv infection
AU762349B2 (en) Method for improving the pharmacokinetics of tipranavir
WO2006034001A2 (en) Methods of treating hiv infection
Bean New drug targets for HIV
Lazdins et al. In Vitro Effect of α1-Acid Glycoprotein on the Anti—Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease Inhibitors
US20120270828A1 (en) Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
JP2013523716A (ja) Ｃｃｒ５拮抗剤、ｈｉｖ−１プロテアーゼ阻害剤及び薬物動態エンハンサーを含む併用療法
Kubin et al. Antiretroviral agents
MXPA06010885A (es) Combinaciones para tratamiento de infeccion de virus de inmunodeficiencia humana (vih)
Stanic et al. Review of antiretroviral agents for the treatment of HIV infection.
JP2020530024A (ja) 組み合わせ並びにその使用及び治療
Sobieszczyk et al. Antiretroviral agents
Kahn The clinical use of didanosine
Koren et al. Scientific basis of antiretroviral therapy
Rawlins et al. Saquinavir
Vermeulen et al. Etravirine
Sension Initial Therapy for Human Immunodeficiency Virus: Broadening the Options
Johns et al. Chemotherapy of human immunodeficiency virus infection
KR20070114806A (ko) 바이러스 감염 치료에의 티오포스포노포름산 및 ｎｒｔｉ의용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110720

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111013

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141021

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4847441

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term